Angiotensin I - konverteringshæmmere, angiotensin II- konverteringsantagonister, diuretika, kort - og langtidsvirkende nitratpræparater, HMG- CoA- reduktasehæmmere, fibrater, syrepumpehæmmere, perorale antidiabetika, acetylsalicylsyre og andre trombocytfunktionshæmmende stoffer.
In pivotal phase III clinical trials the following medicinal products were not restricted and therefore were routinely combined with ivabradine with no evidence of safety concerns: angiotensin converting enzyme inhibitors, angiotensin II antagonists, diuretics, short and long acting nitrates, HMG CoA reductase inhibitors, fibrates, proton pump inhibitors, oral antidiabetics, aspirin and other anti-platelet agents.